9 mmol/L within 24 h of admission (Hypo 1day) or throughout hospitalization (Hypo T) and any glucose < 2
Although rare, symptomatic hypoglycemia can be a serious complication of propranolol treatment
Five hypoglycaemic hyperinsulinaemic patients (three with proven benign insulinoma, one with proven metastasizing insulinoma, one with probable insulinoma not found at
Pharmaceutical agents targeting potential mechanisms that contribute to the development of impaired hypoglycemia awareness have been proposed, including beta
The diabetic subjects were initially rendered euglycemic with a basal insulin infusion
Five hypoglycaemic hyperinsulinaemic patients (three with proven benign insulinoma, one with proven metastasizing insulinoma, one with probable insulinoma not found at surgery) were treated with propranolol for a variable time ranging from two weeks to one year
, for hypertension or ischemic heart disease) could be accomplished without increased Results
The net effect of β-blockade in subjects with diabetes Mechanism of Action
Propranolol is a nonselective beta-adrenoreceptor antagonist, also classified as a class II antiarrhythmic
1 A-1B
1
Because of great heterogeneity in study design and demographics, hypoglycaemia incidence rates varied greatly among studies, occurring in 1
A double-blind, randomised parallel group study (2:1 fashion) was conducted over 4-week period
Pharmaceutical agents targeting potential mechanisms that contribute to the development of impaired hypoglycemia awareness have been proposed, including beta-blockers, opioid receptor antagonists and selective serotonin uptake inhibitors (SSRIs)
Monitor therapy Atenolol is a second-generation beta-1–selective adrenergic antagonist that helps lower the heart rate and blood pressure of an individual while also decreasing myocardial contractility
Propranolol and Hypoglycemia: The Effects of Beta-Adrenergic Blockade on Glucose and Alanine Levels During Fasting
This medicine is a beta-blocker
These medications cross the placenta and may cause physiologic changes in neonates exposed in utero